Table
of Contents
|
|
|
|
|
|
Preface |
ix |
|
SECTION 1 |
BIOLOGY OF HPC
TRANSPLANTATION |
1 |
|
|
Hematopoietic Progenitor Cell Biology |
1 |
|
|
Identification and Enumeration of Progenitor Cells |
3 |
|
|
HLA Typing |
6 |
|
|
References |
8 |
|
SECTION 2 |
COLLECTION OF HPCS |
11 |
|
|
HPCs from Marrow |
11 |
|
|
HPCs from Peripheral Blood |
15 |
|
|
HPCs from Placenta! or Umbilical
Cord Blood |
20 |
|
|
Selection of Unrelated Donor HPCs |
24 |
|
|
References |
26 |
|
SECTION 3 |
CRYOBIOLOGY,
PROCESSING, AND STORAGE OF CRYOPRESERVED HPCS |
33 |
|
|
Cryopreservation Theory |
33 |
|
|
Cryopreservation Techniques |
36 |
|
|
Cryoprotectant Solutions |
41 |
|
|
Cooling and Warming Rates |
44 |
|
|
References |
47 |
|
SECTION 4 |
PROCESSING AND
STORAGE OF NONCRYOPRESERVED HPCS |
51 |
|
|
Processing and Storage Overview |
51 |
|
|
Routine Cell Processing |
52 |
|
|
Processing After Thawing |
55 |
|
|
Cord Blood Processing |
56 |
|
|
Cell Selection Techniques |
63 |
|
|
Tumor Purging |
65 |
|
|
Target Cell Population Enrichment |
67 |
|
|
Testing Techniques |
69 |
|
|
Noncryopreserved Storage |
77 |
|
|
Storage and Transportation of Frozen Cells |
80 |
|
|
Ex-Vivo Expansion of Cells |
83 |
|
|
References |
88 |
|
SECTION 5 |
CLINICAL ASPECTS
OF HPC THERAPY |
103 |
|
|
Infusion of Cell Therapy Products |
103 |
|
|
HPC-C Transplantation |
107 |
|
|
HPC Engraftment |
110 |
|
|
Graft Rejection, GVHD, and Relapse |
114 |
|
|
Donor Leukocyte Infusion |
119 |
|
|
Immune Reconstitution After Stem Cell
Transplantation |
127 |
|
|
The Center for International Blood and Marrow
Transplant Research |
132 |
|
|
References |
137 |
|
SECTION 6 |
ACUTE
COMPLICATIONS OF HPC THERAPY |
155 |
|
|
Chemotherapy and Growth Factors |
155 |
|
|
Establishment of Venous Access |
160 |
|
|
Apheresis Complications |
166 |
|
|
Adverse Effects of Marrow Donation |
171 |
|
|
Adverse Events Associated with Reinfusion |
172 |
|
|
Immunohematologic Effects of ABO-Incompatible HPC
Transplantation |
180 |
|
|
References |
185 |
|
SECTION 7 |
ADVANCES IN
CELLULAR THERAPY AND GRAFT ENGINEERING |
195 |
|
|
Gene Therapy |
195 |
|
|
Mesenchymal Stem Cells |
203 |
|
|
Multipotent Adult Progenitor Cells |
205 |
|
|
Pancreatic Islet Cell Transplantation |
209 |
|
|
Adoptive Immunotherapy (Dendritic
Cell and T-Cell-Mediated Therapy) |
213 |
|
|
References |
217 |
|
SECTION 8 |
REGULATIONS AND
STANDARDS FOR HPC FACILITIES |
225 |
|
|
Development of Cellular Therapy Standards |
225 |
|
|
AABB |
229 |
|
|
American Association of Tissue Banks |
233 |
|
|
American Society for Blood and Marrow
Transplantation |
235 |
|
|
Foundation for the Accreditation of Cellular
Therapy |
238 |
|
|
International Society for Cellular Therapy |
243 |
|
|
National Marrow Donor Program |
245 |
|
|
Food and Drug Administration |
248 |
|
|
State and Local Regulations |
251 |
|
|
Insurance Issues for Blood and Marrow
Transplantation |
254 |
|
|
References |
261 |
|
|
Index |
267 |
|
|
|
|